Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3315149
Max Phase: Preclinical
Molecular Formula: C51H64Cl2N10O11S2
Molecular Weight: 1128.17
Molecule Type: Protein
Associated Items:
ID: ALA3315149
Max Phase: Preclinical
Molecular Formula: C51H64Cl2N10O11S2
Molecular Weight: 1128.17
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC(C)[C@H](NC(=O)[C@@H]1CSSC(C)(C)[C@H](NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCN)C(=O)N[C@@H](Cc2ccc(Cl)c(Cl)c2)C(=O)N1)C(=O)O
Standard InChI: InChI=1S/C51H64Cl2N10O11S2/c1-26(2)41(50(73)74)62-48(71)39-25-75-76-51(3,4)42(63-43(66)33(55)23-40(64)65)49(72)60-36(20-27-11-6-5-7-12-27)45(68)59-38(22-29-24-56-34-14-9-8-13-30(29)34)47(70)57-35(15-10-18-54)44(67)58-37(46(69)61-39)21-28-16-17-31(52)32(53)19-28/h5-9,11-14,16-17,19,24,26,33,35-39,41-42,56H,10,15,18,20-23,25,54-55H2,1-4H3,(H,57,70)(H,58,67)(H,59,68)(H,60,72)(H,61,69)(H,62,71)(H,63,66)(H,64,65)(H,73,74)/t33-,35-,36-,37-,38+,39-,41-,42+/m0/s1
Standard InChI Key: ZDVQIZBVYWRTIH-MSYIYWSESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1128.17 | Molecular Weight (Monoisotopic): 1126.3575 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Carotenuto A, Auriemma L, Merlino F, Yousif AM, Marasco D, Limatola A, Campiglia P, Gomez-Monterrey I, Santicioli P, Meini S, Maggi CA, Novellino E, Grieco P.. (2014) Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor., 57 (14): [PMID:24992374] [10.1021/jm500218x] |
Source(1):